Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta*, Elizabeth A Sugar, Peter J O'Dwyer, Ramesh K Ramanathan, Daniel D Von Hoff, Zeshaan Rasheed, Lei Zheng, Asma Begum, Robert Anders, Anirban Maitra, Florencia McAllister, N V Rajeshkumar, Shinichi Yabuuchi, Roeland F de Wilde, Bhavina Batukbhai, Ismet Sahin, Daniel A Laheru
*Corresponding author for this work
Research output: Contribution to journal › Article › Academic › peer-review
114Citations
(Scopus)
11Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma'. Together they form a unique fingerprint.